Invention Grant
US08314108B2 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
有权
5-（5-（2-（3-氨基丙氧基）-6-甲氧基苯基）-1H-吡唑-3-基氨基）吡嗪-2-甲腈，其药学上可接受的盐，或盐的溶剂合物
- Patent Title: 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
- Patent Title (中): 5-（5-（2-（3-氨基丙氧基）-6-甲氧基苯基）-1H-吡唑-3-基氨基）吡嗪-2-甲腈，其药学上可接受的盐，或盐的溶剂合物
-
Application No.: US12634725Application Date: 2009-12-10
-
Publication No.: US08314108B2Publication Date: 2012-11-20
- Inventor: Francine S. Farouz , Ryan Coatsworth Holcomb , Ramesh Kasar , Steven Scott Myers
- Applicant: Francine S. Farouz , Ryan Coatsworth Holcomb , Ramesh Kasar , Steven Scott Myers
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Danica Hostettler
- Main IPC: A61K31/4965
- IPC: A61K31/4965
Abstract:
The present invention provides an aminopyrazole compound, more particularly, or a pharmaceutically acceptable salt thereof or a solvate of the salt, that inhibits Chk1 and is useful in the treatment of cancer.
Public/Granted literature
- US20110144126A1 COMPOUNDS USEFUL FOR INHIBITING CHK1 Public/Granted day:2011-06-16
Information query
